Verbatim response from ChatGPT
Short answer: most compounded “GLP‑1” drops or home‑made tablets are unreliable and likely won’t work the way prescription GLP‑1 drugs do. There is one FDA‑approved oral GLP‑1 (Rybelsus) that uses a special absorption technology; otherwise the effective drugs are injectables.
Why most compounded oral drops/tablets fail
- GLP‑1 drugs are peptides that are rapidly broken down by stomach acid and digestive enzymes, so plain pills or drops usually have almost no absorption.
- Approved oral semaglutide (Rybelsus) works because it’s combined with an absorption enhancer (SNAC) and has specific dosing instructions; compounding pharmacies typically do not replicate that reliably.
- Compounded products aren’t FDA‑approved: potency, purity, sterility and labeling can be highly variable. Some marketed “drops” studied on social media have been shown to contain little or no active drug or contaminants.
What has been proven to work
- Rybelsus (oral semaglutide, Novo Nordisk) — FDA‑approved oral GLP‑1. Has clinical trial data for blood‑sugar control and modest weight loss. It must be taken exactly as directed (fasted, with a small sip of water, wait before eating). It has lower bioavailability than injectables.
- Injectable GLP‑1 receptor agonists (stronger, more predictable effect): Ozempic/Wegovy (semaglutide, different doses for diabetes vs weight), Trulicity (dulaglutide), and GLP‑1/GIP agonist tirzepatide sold as Mounjaro (for diabetes) and Zepbound (for weight) — these have the most robust weight‑loss and glucose‑lowering effects in trials.
Effectiveness comparison
- Injectables generally produce greater, more consistent glucose lowering and weight loss than oral semaglutide at comparable dosing.
- Rybelsus works for many people with diabetes or modest weight loss goals, but if someone needs larger weight loss, injectable semaglutide or tirzepatide are usually more effective.
Safety and regulatory concerns
- Compounded products: risk of wrong dose, contamination, unexpected side effects. They bypass the safety/efficacy testing that prescription products undergo.
- All GLP‑1 drugs can cause nausea, vomiting, gallbladder issues, and there are rare serious risks (pancreatitis, thyroid C‑cell tumors in rodents); they can interact with other diabetes medications (risk of hypoglycemia). Discuss with a clinician.
What to do next
- Avoid unapproved compounded drops/tablets.
- If you want an oral option, ask your clinician about Rybelsus (semaglutide). If you need stronger weight loss, ask about prescription injectables (Wegovy, Zepbound, Mounjaro, Ozempic) and whether you’re a candidate.
- Talk to your primary care, endocrinologist, or an obesity medicine specialist; consult your pharmacist about approved formulations and insurance/discount programs.
If you want, tell me whether your goal is diabetes control or weight loss and whether you prefer oral vs injectable (or have needle‑phobia or insurance concerns), and I can suggest which FDA‑approved options are worth discussing with your clinician.